reports
- Martin Marandon-Carlhian
- Stephane Houri
- Jakub Krawczyk
- Jakub Krawczyk
- Martin Marandon-Carlhian
- Stephane Houri
- Jan Frederik Slijkerman
- Jeroen van den Broek
- Jesse Norcross
- Nadège Tillier
- Timothy Rahill
- Robert Jan Vos
- ING Helpdesk
Benelux Morning Notes
ABN AMRO: NFLI reaching c.30% level in its ABN stake reduction. ABN AMRO: Relaunch of Belgium private banking using MeesPierson brand. Elia: FY25 profit outlook unchanged, minor reduction in capex. Greenyard: Disappointing 2H24/25, guidance lowered. NN Group, ASR: Parliament votes against amendment to Dutch Pension Reform
- Thomas Vranken
Onward Medical FIRST LOOK: Two additional BCI implants completed
Onward has successfully completed the 4th and 5th implants of its ARC-BCI brain-computer interface in two additional spinal cord injury patients. The ARC-BCI system combines Onward's ARC-IM neurostimulation platform with Clinatec's WIMAGINE BCI device to enable AI-driven, thought-controlled movement. With promising prior data on safety and signal stability, WIMAGINE is seen as a strong contender in the competitive BCI space. We reiterate our €10.4 TP and Buy rating.
- Guy Sips
- Kristof Samoy
- Lynn Hautekeete
- Michiel Declercq
- Thomas Vranken
- Wim Lewi
Elia Group 1Q25 Trading update
In its 1Q25 trading update, Elia confirmed its FY25 net group profit outlook between EUR 490m and 540m. Elia now uses a lower base rate for the GE regulatory return of 2.30% and 2.80% for ETB. At the FY24 results the Capex FY24-28 was raised by 1.6bn to 31.6bn. 50Hz typically has a higher ROE (8-10%) vs. ETB (7-8%). WindGrid is evaluating Forward Power Offshore, which holds a 25% stake in Leading Light Wind, a project currently facing uncertainty due to executive orders from the Trump Administr...
- Thijs Berkelder
ONWARD Medical Advances Brain-Computer Interface Leadership with Fourt...
ONWARD Medical Advances Brain-Computer Interface Leadership with Fourth and Fifth Successful BCI Implants Groundbreaking procedures extend ONWARD’s leadership in the rapidly emerging brain-computer interface (BCI) fieldARC-BCI Therapy is designed to restore thought-driven movement after spinal cord injury and other movement disabilitiesONWARD’s BCI breakthroughs were recently featured on CBS 60 Minutes with Anderson Cooper EINDHOVEN, the Netherlands, May 21, 2025 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD and US OTCQX: ONWRY), the leading neurotechnology company pioneering t...
CMB.TECH announces Q1 2025 results
CMB.TECH announces Q1 2025 results CMB.TECH ANNOUNCES Q1 2025 RESULTS 1 BILLION USD CONTRACT BACKLOG ADDED ANTWERP, Belgium, 21 May 2025 – CMB.TECH NV (“CMBT”, “CMB.TECH” or “the Company”) (NYSE: CMBT & Euronext: CMBT) reported its non-audited financial results today for the first quarter ended 31 March 2025. HIGHLIGHTS Financial highlights: Profit of USD 40.4 million in Q1 2025CMB.TECH increases its contract backlog by USD 921 million (to USD 2.94 billion) Corporate highlights: CMB.TECH buys Hemen stake in Golden OceanTerm sheet signed for a stock-for-stock merger transac...
IBA and PET Pharm Bio sign contract to install a Cyclone® IKON in Taiw...
IBA and PET Pharm Bio sign contract to install a Cyclone® IKON in Taiwan The Cyclone® IKON is IBA’s high energy and high-capacity cyclotron which offers the largest energy spectrum for the production of PET and SPECT isotopes from 13 MeV to 30 MeV Louvain-La-Neuve, Belgium, May 21, 2025 – (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of radiopharmaceutical production solutions, announces it has signed a contract with PET Pharm Bio to install a PET and SPECT isotopes production center in Taipei, Taiwan. PET Ph...
IBA et PET Pharm Bio signe un contrat pour l’installation d’un Cyclone...
IBA et PET Pharm Bio signe un contrat pour l’installation d’un Cyclone® IKON à Taiwan Le Cyclone® IKON est le cyclotron haute énergie et haute capacité d'IBA qui offre le plus grand spectre d'énergie pour la production d’isotopes TEP et TEMP de 13 MeV à 30 MeV. Louvain-la-Neuve, Belgique, le 21 mai 2025 – IBA (Ion Beam Applications S.A., EURONEXT), le leader mondial des technologies d’accélération de particules et le principal fournisseur de solutions de production de radiopharmaceutiques, annonce avoir signé un contrat avec PET Pharm Bio pour installer un centre de production d'isotopes...
- ING Helpdesk
IBA – ACQUISITION OF OWN SHARES
IBA – ACQUISITION OF OWN SHARES Immediate Release – May 19th, 2025 Louvain-la-Neuve, Belgium, May 19th, 2025 - In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, Ion Beam Applications SA (“IBA”) hereby discloses information in relation to its share buyback program announced on March 24th, 2025. Under this program, IBA has requested a financial intermediary to repurchase up to 650,000 IBA ordinary shares on its behalf under the terms of a mandate with validity until December 31st, 2025, effective as from March ...
IBA – ACQUISITION D’ACTIONS PROPRES
IBA – ACQUISITION D’ACTIONS PROPRES Publication immédiate – 19 mai 2025 Louvain-la-Neuve, Belgique, 19 mai 2025 - Conformément à l'article 8:4 de l'arrêté royal du 29 avril 2019 portant exécution du Code belge des sociétés et associations, Ion Beam Applications SA ("IBA") communique par la présente certaines informations relatives à son programme de rachat d'actions annoncé le 24 mars 2025. Dans le cadre de ce programme, IBA a demandé à un intermédiaire financier de racheter en son nom un maximum de 650.000 actions ordinaires IBA selon les termes d'un mandat valable jusqu'au 31 décembr...
- Hilde Van Boxstael
- Lynn Hautekeete
- Thomas Couvreur
- Wim Lewi
IBA launches CASSY®, a new compact radiochemistry module to enhance ef...
IBA launches CASSY®, a new compact radiochemistry module to enhance efficiency in radiopharmaceuticals production Louvain-La-Neuve, Belgium, 13 May 2025 - IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the leading provider of radiopharmaceutical production solutions, today announces the launch of CASSY®, a compact synthesizer designed to streamline radiopharmaceutical production processes. This new IBA solution is set to transform the way radiometals and radiotracers are produced. CASSY®, Compact Automated Scalable SYnthesis, enhanc...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.